Menu

Running from Cancer?

At the American Association for Cancer Research annual meeting, researchers review the evidence that exercise has antitumor benefits.

Apr 18, 2016
Jef Akst

FLICKR, D26B73Can exercising help treat cancer? The short answer is: we don’t know. At a session today (April 18) at the annual conference of the American Association for Cancer Research (AACR) in New Orleans, researchers discussed the epidemiological and preclinical work that has suggested exercise might be beneficial for cancer patients, and emphasized the need for more research to understand this complex relationship.

“We’ve got to do a better job of getting better data,” session chair Lee Jones of the Memorial Sloan Kettering Cancer Center said. “We don’t even know to date if exercise has any efficacy in terms of anticancer benefits.”

In a review of the existing epidemiologic literature in this area, Christine Friedenreich of the University of Calgary, Canada, pointed to 10 studies on breast cancer patients, six studies involving colorectal cancer patients, and three studies on prostate cancer patients, which collectively provide “very strong evidence” of an antitumor benefit of physical activity, she said. However, these studies relied almost exclusively on subjective measures of exercise and failed to control for a variety of confounding factors, such as prediagnosis activity levels, sedentary behavior, and competing risks of mortality. Friedenreich outlined two ongoing studies, the AMBER study and the RUBY study, which aim to correct for these shortcomings in cohorts of 1,500 and 1,200 newly diagnosed breast cancer patients, respectively. “We’re still very much at an early stage in understanding how physical activity is related to cancer survival,” she said. “There’s some very positive and intriguing results to date but there’s a lot of work that can still be done.”

Mark Dewhirst of Duke University in North Carolina focused on work investigating the effects of exercise in mouse models of cancer during his AACR talk. Unfortunately, he noted, among 53 papers on the topic, he found “tremendous heterogeneity,” making it “hard to come up with any kind of consistent pattern.” Still, several studies individually point to a positive effect of physical activity on tumor progression in mice, he noted. In one study, “exercise worked as well as chemotherapy,” Dewhirst said, and the combination of chemotherapy and exercise had even better outcomes.

Animal research allows scientists to probe the potential mechanisms underlying the effects of exercise on cancer outcome. Exercise appears to increase vascular profusion, and to result in more mature vasculature, Dewhirst noted. In addition, studies on animals have found a decrease in cellular oxygen consumption, possibly related to an increase in apoptosis. Taken together, it’s not surprising, then, that tumors in these animals experienced decreased hypoxia.

Going forward, Jones emphasized the need for a more traditional approach to studying the role of exercise in cancer. Even though this sort of intervention is not regulated by the US Food and Drug Administration (therefore, preclinical data are not needed to begin human trials), research efforts could be more fruitful if scientists used epidemiologic results to inform preclinical testing, which in turn could help guide the design of clinical trials. “An adoption of a translational approach, just like we do in the drug world, is absolutely essential,” Jones said.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.